Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)

Inclusion Criteria:

• Informed consent

• Patient will receive radiation therapy to considered moderate risk (upper abdomen,upper and half body irradiation) or low risk (lower thorax and pelvis) emetogenicpalliative radiotherapy.

• Patients will be grouped according to nausea and vomiting status at baseline asfollows:

• Group 1: Patient is experiencing no nausea and vomiting at baseline

• Group 2: Patient is experiencing at least mild nausea and/or at least mildvomiting at baseline

Exclusion Criteria:

• Patient is scheduled to receive cranial radiation therapy during or within 10 daysfollowing completion of protocol RT.

• Patient received cranial RT within 7 days prior to commencement of protocol RT.

• Patient is scheduled to receive chemotherapy during or within 10 days followingcompletion of protocol RT.

• Patient received moderately or highly emetogenic chemotherapy within 7 days prior tocommencement of protocol RT.

• Patient is scheduled to change regimen/dose or start the use of low dosecorticosteroids (inhaled or topical permitted), or other medications considered tohave antiemetic properties within 48 hours prior to protocol RT.

• Patient is scheduled to change regimen/dose or start the use of low dosecorticosteroids (inhaled or topical permitted), or other medications considered tohave antiemetic properties during or within 10 days following completion of protocolRT.

• Concurrent use of corticosteroids during protocol RT is not permitted, unless low dosecorticosteroids (hydrocortisone) are used for cancer treatment

• Patient is allergic to protocol medication.

• Patient has a Karnofsky Performance Status score <40.

• Patient is a woman who is pregnant or of childbearing potential and is not usingcontraceptive measures.